BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khanh do T, Mekata E, Mukaisho K, Shimizu T, Tatsuta T, Sugihara H, Endo Y, Kurumi Y, Tani T. Myeloid cells positive for CD10 at invasion front can predict poor outcome in stage II colorectal cancer. Int J Clin Oncol 2012;17:240-9. [PMID: 21773689 DOI: 10.1007/s10147-011-0281-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Foda AAM, Alamer HA, Ikram N, Helali HA, Fayad FS, Hussian SW, Abdelwahab K, Akl T, Emarah Z, Ramez AM. Expression of CD10 and CD15 in colorectal mucinous and signet ring adenocarcinomas and its relation to clinicopathological features and prognosis. Cancer Biomark 2021. [PMID: 34487022 DOI: 10.3233/CBM-210067] [Reference Citation Analysis]
2 Khanh do T, Mekata E, Mukaisho K, Sugihara H, Shimizu T, Shiomi H, Murata S, Naka S, Yamamoto H, Endo Y, Tani T. Transmembrane mucin MUC1 overexpression and its association with CD10⁺ myeloid cells, transforming growth factor-β1 expression, and tumor budding grade in colorectal cancer. Cancer Sci 2013;104:958-64. [PMID: 23566254 DOI: 10.1111/cas.12170] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
3 Jang TJ, Park JB, Lee JI. The Expression of CD10 and CD15 Is Progressively Increased during Colorectal Cancer Development. Korean J Pathol 2013;47:340-7. [PMID: 24009629 DOI: 10.4132/KoreanJPathol.2013.47.4.340] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
4 Seki-Soda M, Sano T, Ogawa M, Yokoo S, Oyama T. CD15+ tumor infiltrating granulocytic cells can predict recurrence and their depletion is accompanied by good responses to S-1 with oral cancer. Head Neck 2021;43:2457-67. [PMID: 33893751 DOI: 10.1002/hed.26712] [Reference Citation Analysis]
5 Lino-Silva LS, Salcedo-Hernández RA, Gamboa-Domínguez A. Tumour budding in rectal cancer. A comprehensive review. Contemp Oncol (Pozn) 2018;22:61-74. [PMID: 30150882 DOI: 10.5114/wo.2018.77043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]